Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 17/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 11/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13912128 | 0.97 | ABCG2 (0.94) | ABCG2ABCB1TP53 | |
| SCHEMBL13912106 | 0.96 | ABCG2 (1.00) | ABCG2ABCB1TP53 | |
| SCHEMBL13882931 | 0.93 | ABCG2 (0.87) | ABCG2ABCB1TP53 | |
| SCHEMBL13882930 | 0.93 | ABCG2 (0.87) | ABCG2ABCB1TP53 | |
| SCHEMBL13882458 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1 | |
| SCHEMBL13882380 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1TP53 | |
| SCHEMBL13912117 | 0.92 | ABCG2 (0.85) | ABCG2ABCB1 | |
| SCHEMBL13912125 | 0.91 | TP53 (0.84) | ABCG2ABCB1TP53 | |
| SCHEMBL13882928 | 0.91 | ABCG2 (0.82) | ABCG2ABCB1TP53 | |
| SCHEMBL13882456 | 0.91 | ABCG2 (0.85) | ABCG2ABCB1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2022-06-30 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| US-11202775-B2 | Methods for treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2021-12-21 | — | — | US | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2214485-B1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2214485-A1 | METHODS FOR TREATMENT OF CANCER | Minerva Biotechnologies Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009042815-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042815-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069367-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885TP53 1/4885 |
| US-11202775-B2 | Methods for treatment of cancer | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885TP53 1/4885 |
| US-20220202786-A1 | METHODS FOR TREATMENT OF CANCER | TP53, TOP2B, BRCA1 | ABCG2 1889/4885ABCB1 510/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.